GVS (GVS) Q2 2025 earnings summary

Executive summary

• Achieved strongest quarterly profitability since Q4 2021, with H1 2025 revenues of €215.6M, up 1.7% year-over-year at constant FX, driven by Transfusion Medicine and Safety growth, offsetting Mobility declines.

• Adjusted EBITDA rose 4.1% to €54.2M, margin improved to 25.1% for H1 and 26.2% in Q2, the highest since Q4 2021.

• Adjusted net profit (excluding FX) increased 16.2% year-over-year to €26.2M, margin up to 12.1% from 10.5%.

• Net profit was €1.0M, significantly down from €19.0M in H1 2024, mainly due to adverse exchange rate effects.

• Strategic plan in development to address legacy low-margin businesses and optimize portfolio.

Financial highlights

• Revenue grew to €215.6M from €214.8M year-over-year; adjusted EBITDA margin up 90 bps to 25.1%.

• Adjusted EBIT reached €39.5M, up 4.9% year-over-year, with an 18.3% margin.

• Net financial debt increased to €268.0M, mainly due to the Haemonetics acquisition.

• Cash flow from operating activities was €11.9M, with significant investments and a net cash outflow of €38.8M for the period.

• ROE: 0% (vs. 11%), ROI: 11% (unchanged), ROS: 18% (vs. 17%).

Outlook and guidance

• Full-year 2025 guidance updated to mid- to high single-digit turnover growth at constant FX, with acceleration in H2 from Whole Blood revenues.

• Adjusted EBITDA margin expected to rise by 150–250 bps versus 2024, including tariff impacts.

• Leverage ratio projected at ~2.2x by year-end, factoring in a €20M buyback.

• Tariff impacts in H1 2025 (~€350K) expected to be offset by price increases in H2.

• Dividend distribution remains a goal by year-end, subject to H2 performance.